Tempus Partners with IFLI to Advance Development of Targeted Therapies for Follicular Lymphoma
Tempus AI, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Join Forces to Accelerate Development of Targeted Therapies for Follicular Lymphoma
Tempus AI, Inc., a pioneering technology company at the forefront of artificial intelligence (AI) in precision medicine and patient care, has announced a groundbreaking collaboration with the Institute for Follicular Lymphoma Innovation (IFLI). The IFLI is a global, non-profit foundation dedicated to advancing the treatment landscape for follicular lymphoma (FL), a common form of non-Hodgkin lymphoma. This strategic partnership aims to accelerate the development of innovative treatments for FL patients by creating a state-of-the-art, real-world data library using a comprehensive range of multimodal, de-identified data. Through Tempus’ cutting-edge data analytics platform, Lens, this collaboration seeks to leverage AI-driven insights to help researchers and clinicians better understand the disease and ultimately improve patient outcomes.
Follicular lymphoma remains a challenging condition, with many patients experiencing disease progression despite treatment. The goal of this collaboration is to provide valuable insights that could transform the treatment of FL, especially for patients who face particularly difficult outcomes. With a strong commitment to developing solutions that improve the lives of individuals suffering from FL, this partnership offers new hope for the development of targeted therapies tailored to the diverse biology of the disease.
Dr. Kate Sasser, Chief Scientific Officer at Tempus, emphasized the power of combining IFLI’s specialized focus on follicular lymphoma with Tempus’ expertise in AI-enabled solutions. “This collaboration exemplifies the potential that arises when organizations with complementary strengths come together. IFLI’s dedication to follicular lymphoma research and our advanced technologies in AI-driven analytics will provide unprecedented insights into FL biology, which could lead to the development of more effective, personalized treatments,” said Sasser. “We are excited to explore this new model of collaboration with foundations to advance the understanding of FL and contribute meaningfully to the fight against this disease.”
The collaboration’s immediate focus will be on generating prospective, multimodal data specific to patients with follicular lymphoma who experience disease progression within 24 months of receiving initial treatment, a subgroup of patients known as POD24. These high-risk patients, who are at greater risk of aggressive disease progression, represent a significant unmet need in FL research and treatment. Through a Tempus-sponsored study, the collaboration will gather real-world data on POD24 patients to enhance researchers’ understanding of the factors contributing to disease progression, as well as provide insights into the molecular and clinical characteristics that may influence treatment responses.
David McCullagh, Managing Director at IFLI, expressed his enthusiasm for the partnership. “We are thrilled to announce our collaboration with Tempus, whose leadership in AI-driven precision medicine makes them the perfect partner for this critical work,” said McCullagh. “Together, we are creating a robust, de-identified FL database that will accelerate both research and drug development. This collaborative effort will serve as a vital resource for researchers working to understand the complexities of follicular lymphoma and develop the next generation of therapies to treat and cure FL patients.”
The establishment of a centralized, multimodal FL data library has the potential to revolutionize the way researchers approach FL research and treatment development. Multimodal data refers to the integration of diverse types of data, such as genomics, clinical, imaging, and molecular data, to create a more comprehensive understanding of the disease. By combining these data sources, researchers can gain a deeper understanding of the heterogeneity of FL and how it progresses in different patients. This comprehensive view is essential for the identification of novel therapeutic targets and the development of precision medicines that can be tailored to the unique characteristics of individual patients.
The use of AI in analyzing large, complex datasets further enhances the ability to uncover meaningful patterns and insights that might otherwise go unnoticed. Tempus’ advanced AI algorithms are designed to mine vast amounts of data quickly and accurately, offering researchers valuable insights into disease biology, treatment response, and potential drug targets. This technology has the potential to significantly accelerate the drug discovery and development process, ultimately leading to more effective treatments for follicular lymphoma.
The collaboration also underscores the importance of data sharing and collaboration in advancing medical research. By providing the research community with access to a centralized, high-quality database, Tempus and IFLI are helping to break down the barriers that often hinder progress in rare diseases like follicular lymphoma. Researchers will have the ability to explore the data from a variety of perspectives, uncovering new insights and advancing our collective understanding of the disease. This collaborative approach not only accelerates scientific discovery but also helps ensure that the benefits of these insights can be translated into real-world treatments for patients.
This new partnership is also a significant step forward in the ongoing efforts to personalize medicine for patients with follicular lymphoma. FL is a highly heterogeneous disease, meaning that it manifests differently in different patients and may respond to treatment in various ways. A deeper understanding of the disease’s biology, combined with precision medicine approaches, will enable clinicians to offer more targeted therapies that are better suited to the individual needs of patients. By developing treatments that are tailored to each patient’s unique disease profile, it is hoped that outcomes can be improved, and the burden of FL on patients and their families can be reduced.
For Tempus, this collaboration represents another step in its mission to transform healthcare through technology. The company is committed to advancing precision medicine by leveraging AI, data, and analytics to enable more accurate diagnoses, better treatment decisions, and improved patient outcomes. By partnering with organizations like IFLI, Tempus is expanding its efforts to apply its expertise to a wide range of diseases, including rare and complex conditions like follicular lymphoma.
IFLI’s commitment to improving the lives of FL patients is rooted in its dedication to advancing research and therapeutic development. By focusing on the most challenging aspects of FL, such as high-risk patients and disease progression, IFLI is working to address the critical gaps in current treatment options. Through this collaboration with Tempus, IFLI is taking an important step toward realizing its vision of a world where FL patients have access to effective, personalized therapies and better overall outcomes.
The creation of this multimodal FL data library will not only benefit researchers but also have a broader impact on the field of oncology. By improving our understanding of FL and advancing the development of targeted treatments, this collaboration could serve as a model for other types of cancer research. It is a prime example of how cutting-edge technology and data-driven approaches can be used to make significant strides in the fight against cancer.
As the collaboration progresses, Tempus and IFLI will continue to explore new ways to leverage their combined expertise in AI, data analytics, and clinical research to push the boundaries of FL research and drug development. Together, they are committed to driving innovation and improving the lives of those affected by follicular lymphoma.
In conclusion, the partnership between Tempus and IFLI marks a significant milestone in the ongoing efforts to advance the treatment of follicular lymphoma. By combining Tempus’ AI-powered data analytics platform with IFLI’s deep expertise in FL research, the collaboration is poised to accelerate the discovery of new treatments and ultimately improve the outcomes for FL patients worldwide. With the shared goal of better understanding the disease and developing personalized therapies, this partnership has the potential to make a lasting impact on the future of FL treatment and care.
